Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pneumococcal 13-valent conjugate vaccine (Pfizer)
- Development stage
- Phase 4
- Lead developer
- Pfizer
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
Pneumococcal 13-valent conjugate vaccine is a biologic vaccine used for active immunization to prevent invasive disease and pneumonia caused by Streptococcus pneumoniae. It targets thirteen specific serotypes of the bacterium (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F). The mechanism of action involves stimulating the immune system to produce antibodies against these serotypes through a protein-polysaccharide conjugation approach. The primary indication is prevention of serious infections such as meningitis and bacteremia in both children (from six weeks old) and adults. Pfizer developed the original version (Prevnar/Prevnar 13), with other versions developed by companies like Walvax Biotechnology[1][3][5][6][7].
- Brand names
- Prevnar 13Prevnar13Prevnar-13WEUPHORIA
- Other names
- pneumococcal conjugate vaccine 13-valent13-valent pneumococcal conjugate vaccine
02
Targets
CPS (Streptococcus pneumoniae capsular polysaccharide)
Beyond the preview
Go deeper on pneumococcal 13-valent conjugate vaccine (Pfizer).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pneumococcal 13-valent conjugate vaccine (Pfizer).